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Abstract Sensitization of myofascial pain pathways may play an important role in the pathophysiology of chronic headache. Animal studies have shown that sensitization of pain pathways may be caused by or associated with activation of neuronal nitric oxide synthase (nNOS) and the generation of nitric oxide (NO). Furthermore, it has been shown that NOS inhibitors reduce central sensitization in animal models of persistent pain. On the basis of these findings, we investigated the analgesic effect of the NOS inhibitor, L-N G -methyl arginine hydrochloride, and demonstrated that this drug significantly reduced headache as well as myofascial factors in patients with chronic tension-type headache. In addition, we demonstrated that infusion of the NO donor, glyceryl trinitrate, induces headache in these patients, probably by enhancing the sensitizing effect of pre-existing myofascial input. These studies strongly indicate that NO plays a crucial role in the pathophysiology of tension-type headache. We suggested that the analgesic effect of NOS inhibition in patients with chronic tension-type headache is most likely due to reduction of central sensitization at the level of the spinal dorsal horn or trigeminal nucleus, or both. Furthermore, these data suggest that inhibition of NOS may become a novel means of future treatment of chronic headache.
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Nitric oxide and central sensitization in animal models
The freely diffusible gas nitric oxide (NO) is a messenger molecule involved in various biological functions [10] , including neurotransmission [11] . NO contributes to sensory transmission in the peripheral [12] and central nervous system [13] . Furthermore, animal studies have shown that central sensitization may be caused by or associated with activation of neuronal nitric oxide synthase (NOS) and the generation of NO [13] [14] [15] . Moreover, prolonged elevation of NO within the spinal dorsal horn is important in maintaining the central sensitization [16] . Finally, it has been shown that inhibition of NOS reduces central sensitization in animal models of persistent pain [14, 17, 18] and that nociceptive responses in these models are enhanced by NO donors [19, 20] .
Inhibition of NOS in chronic tension-type headache
In order to test the hypothesis that inhibition of NO and thereby central sensitization would reduce chronic headache, we investigated the analgesic effect of the NOS inhibitor L-N Gmethyl arginine hydrochloride (L-NMMA) in patients with chronic tension-type headache [21] . In a double-blind, placebo-controlled crossover study, 16 patients received L-NMMA or placebo on 2 days. L-NMMA reduced headache intensity significantly more than placebo (Fig. 1) . To explore the mechanisms of this analgesic effect we also studied myofascial factors in relation to NOS inhibition [22] . We found that both muscle hardness and tenderness were significantly reduced following treatment with L-NMMA, while there was no significant reduction at any time after treatment with placebo (Figs. 2, 3) . We suggest that the antinociceptive effect of NOS inhibition in patients with chronic tension-type headache is most likely due to reduction of central sensitization at the level of the spinal dorsal horn/trigeminal nucleus [21] [22] [23] .
NO induction in chronic tension-type headache
It is an important question whether NO may induce or enhance central sensitization in patients with chronic tensiontype headache. We aimed to investigate this using the NO donor, glyceryl trinitrate (GTN), model of experimental headache [24] . Sixteen patients and 16 healthy controls were Fig. 3 Percentage changes in total tenderness score (TTS) in patients with chronic tension-type headache. The TTS tended to be reduced following treatment with L-NMMA compared with placebo (p=0.11). Within each treatment, the TTS was significantly reduced at 60 and 120 min after the start of the infusion of L-NMMA, while there was no significant changes at any time after treatment with placebo. **p<0.01 compared with baseline (time=0). The plots represent mean scores. (Modified from [22] with permission) Fig. 4 Median headache intensity over time during (20 min) and after infusion of glyceryl trinitrate (GTN) and placebo in patients with chronic tension-type headache. Patients were allocated randomly to receive 0.5 µg/kg GTN per min or placebo on 2 headache-free days separated by at least 1 week. Headache was scored on a 10-point Verbal Rating Scale (VRS). The area under the headache curve (intensity x duration) on a GTN day was significantly higher than on a placebo day (p=0.008). The headache intensity reached its peak value at 8 h after the start of the GTN infusion. (Reproduced from [24] with permission) randomized to receive intravenous infusion of GTN over 20 min. Patients developed significantly stronger headache on a GTN day than on a placebo day (Fig. 4) . Furthermore, patients developed significantly stronger headache after GTN than controls. However, the most interesting finding of this study was that GTN infusion in patients resulted in a biphasic response with an immediate and a delayed headache (8 h after start of infusion) (Fig. 4) . Moreover, in 87% of patients the delayed headache fulfilled tension-type headache criteria [24] . It is most likely that immediate headache after infusion of GTN originates from direct action of NO on perivascular sensory nerves or from NO-induced arterial dilatation, or both [24] , while the delayed headache may be due to augmentation of pre-existing central sensitization [24] .
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Concluding remarks and future perspectives
In summary, these data demonstrate that the administration of a NOS inhibitor results in the reduction of headache, pericranial myofascial tenderness, and muscle hardness in patients with chronic tension-type headache. Since a reduction of central sensitization is the most likely mechanism of action of L-NMMA, this supports the importance of central sensitization in chronic tension-type headache. It is probable that reduction of central sensitization may become a new means of future treatment of chronic headache as well as other chronic pain disorders. However, there are still unanswered questions which should be addressed in future studies. Thus, L-NMMA inhibits all three types of NOS (endothelial NOS, neuronal NOS, inducible NOS) and study of selective inhibitors of NOS is needed to find out which type of NOS is involved in chronic head pain and its exact site of action. We are only beginning to understand the complex mechanisms leading to chronic tension-type headache, but the most-recent data obtained in clinical studies are promising and hopefully will lead to new treatment modalities in chronic head pain.
